Evidence map›Paper›PMID 42187603›Full record

ArticleCurrent oncology (Toronto, Ont.)2026

Lenvatinib Combined with New FP Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma: Clinical Efficacy, Vascular Remodeling, and Implications for Immuno-Oncology-Systemic Combination Therapy.

Susumu Maruta, Yohei Koshima, Yuji Debari, Chihei Sugihara, Gou Takahata, Ryo Tamura, Tadashi Ohshima, Yuji Ono, Yuho Morita, Tomoki Chiba and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Susumu MarutaDepartment of Gastroenterology, Saitama Red Cross Hospital, 1-5 Shintoshin, Chuo-ku, Saitama 330-8553, Japan.
Yohei KoshimaDepartment of Gastroenterology, Saitama Red Cross Hospital, 1-5 Shintoshin, Chuo-ku, Saitama 330-8553, Japan.
Yuji DebariDepartment of Gastroenterology, Saitama Red Cross Hospital, 1-5 Shintoshin, Chuo-ku, Saitama 330-8553, Japan.
Chihei SugiharaDepartment of Gastroenterology, Saitama Red Cross Hospital, 1-5 Shintoshin, Chuo-ku, Saitama 330-8553, Japan.
Gou TakahataDepartment of Gastroenterology, Saitama Red Cross Hospital, 1-5 Shintoshin, Chuo-ku, Saitama 330-8553, Japan.
Ryo TamuraDepartment of Gastroenterology, Saitama Red Cross Hospital, 1-5 Shintoshin, Chuo-ku, Saitama 330-8553, Japan.
Tadashi OhshimaDepartment of Gastroenterology, Saitama Red Cross Hospital, 1-5 Shintoshin, Chuo-ku, Saitama 330-8553, Japan.
Yuji OnoDepartment of Gastroenterology, Saitama Red Cross Hospital, 1-5 Shintoshin, Chuo-ku, Saitama 330-8553, Japan.
Yuho MoritaDepartment of Gastroenterology, Saitama Red Cross Hospital, 1-5 Shintoshin, Chuo-ku, Saitama 330-8553, Japan.
Tomoki ChibaDepartment of Gastroenterology, Saitama Red Cross Hospital, 1-5 Shintoshin, Chuo-ku, Saitama 330-8553, Japan.
Satoru IshidaDepartment of Gastroenterology, Saitama Red Cross Hospital, 1-5 Shintoshin, Chuo-ku, Saitama 330-8553, Japan.
Hideto ImaiDepartment of Gastroenterology, Saitama Red Cross Hospital, 1-5 Shintoshin, Chuo-ku, Saitama 330-8553, Japan.
Keisuke WatanabeDepartment of Gastroenterology, Saitama Red Cross Hospital, 1-5 Shintoshin, Chuo-ku, Saitama 330-8553, Japan.
Ryo ChinzeiDepartment of Gastroenterology, Saitama Red Cross Hospital, 1-5 Shintoshin, Chuo-ku, Saitama 330-8553, Japan.
Masanori TakahashiDepartment of Gastroenterology, Saitama Red Cross Hospital, 1-5 Shintoshin, Chuo-ku, Saitama 330-8553, Japan.
Yoshihiko OokaChiba Chuo Clinic, 1-1 Honchiba-cho, Chuo-ku, Chiba 260-0014, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, HepatocellularLiver NeoplasmsPhenylurea CompoundsQuinolinesVascular RemodelingAgedFemaleHepatic ArteryHumansInfusions, Intra-ArterialMaleMiddle AgedRetrospective StudiesTreatment OutcomelenvatinibPhenylurea CompoundsQuinolineshepatic arterial infusion chemotherapyhepatocellular carcinomaimmuno-oncologyLEN-New FPlenvatinibNew FPvascular remodeling

Identifiers

PMID42187603
PMCPMC13206129

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.